Titan Medical Promotes Globally Recognized Intellectual Property Strategy Leader to Vice President and General Counsel
25 Junho 2020 - 09:00AM
Business Wire
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD)
(Nasdaq: TMDI), a medical device company focused on the design
and development of single-port robotic surgical technologies,
announces that its head of intellectual property, Jasminder Brar,
has been promoted to Vice President of Legal, IP and Strategic
Initiatives, and General Counsel. Mr. Brar has lead Titan’s
strategic IP efforts since 2011 and is recognized as a global IP
strategy leader, having been named to the IAM Strategy 300: The
World’s Leading IP Strategists since 2015. In this expanded role,
Mr. Brar will also serve as the Company’s Corporate Secretary.
“I am pleased to promote Jasminder to our executive team, where
his experience, skills and strategic insight will be invaluable to
our success,” said David McNally, President and CEO of Titan
Medical. “Throughout his time at Titan, Jasminder has helped drive
innovation and create value for all stakeholders of Titan, and he
has repeatedly demonstrated his top-notch legal and business
abilities, most recently evidenced through his leadership roles in
negotiating the license and development agreements with Medtronic
as well as settling ongoing litigation. Along with other key
members of our team, he will play an active role in ensuring the
success of the development project with Medtronic and in the
development of our single-port robotic system. Congratulations to
Jasminder.”
Mr. Brar joined Titan in 2011 as IP Counsel, its first and only
legal counsel, before becoming the Director of Strategic
Development and IP, and Legal Counsel in 2014. Prior to joining
Titan, Mr. Brar was an associate with the law firm of Smart &
Biggar LLP in Vancouver, British Columbia, where he worked on a
variety of intellectual property related matters. Before practising
law, he worked as an engineer and in product marketing with
National Semiconductor in Santa Clara, California. Mr. Brar
received a Bachelor of Science in Computer Engineering (with
distinction) and a Bachelor of Laws (LL.B.), both from the
University of Manitoba in Winnipeg, Manitoba.
The IAM Strategy 300 guide can be found at
www.iam-media.com/directories/strategy300/.
About Titan
Titan Medical Inc. is focused on robotic-assisted technologies
for application in minimally invasive surgery (“MIS”). Titan is
developing a single-port robotic surgical system comprised of a
surgeon-controlled patient cart that includes a dual-view camera
system with 3D and 2D high-definition vision systems and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an ergonomic interface to the
patient cart and a 3D high-definition endoscopic view of the MIS
procedure. Titan intends to initially pursue gynecologic surgical
indications for use with its single-port robotic surgical
system.
For more information, visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws. Such
statements reflect the current expectations of management of the
Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Report on Form 20F dated March 30, 2020 (which may be viewed at
www.sedar.com and at www.sec.gov). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. These factors should be considered
carefully, and prospective investors should not place undue
reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the Company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
Company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200625005386/en/
Stephen Randall Chief Financial Officer +1-416-548-7522
stephen@titanmedicalinc.com
Titan Medical (NASDAQ:TMDI)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Titan Medical (NASDAQ:TMDI)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024